시장보고서

상품코드

1701282

급성 골수성 백혈병 치료 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 03월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 규모와 동향

세계의 급성 골수성 백혈병 치료 시장 규모는 2024년에 34억 7,000만 달러에 달했으며, 2025-2030년에 걸쳐 CAGR 10.6%를 나타낼 것으로 예측됩니다.

급성 골수성 백혈병의 이환율 상승과 선진적인 치료에 대한 요구 증가는 유전자 변이, 건강에 해로운 라이프 스타일, 벤젠 등의 유해 화학물질에 대한 지속적인 노출, 방사선 피폭 등의 요인에 기인하고 있습니다.

급성 골수성 백혈병(AML) 치료의 진보는 지금까지 표적 치료의 진보가 최전선에 있었습니다. 예를 들어 FLT3-ITD 양성 급성 골수성 백혈병과 새로 진단받은 환자들에 대해 FDA는 2023년 7월에 키잘티닙(밴프리타)을 미국에서 승인하고 표준 화학요법과 병행하여 치료 옵션을 늘렸습니다.

베네토크락스와 아자시티딘과 다른 메틸화 억제제의 병용 요법은 AML 환자의 생존율을 높이는 유망한 결과를 보여줍니다. 그리고 치료 효과를 극대화하는 연구에도 주목을 받고 있습니다. 이와 같은 혁신적인 접근법은 환자의 예후 개선을 약속하는 다면적인 치료 전략의 개발에 대한 헌신이 높아지고 있음을 보여줍니다.

또한, CAR-T 세포 요법을 포함한 면역 요법의 동향은 AML 치료의 혁명적 경향을 보여줍니다. AML과 관련된 유전자 변이의 해명이 진행됨으로써, KMT2A나 NPM1과 같은 특정 변이를 메닌 억제제로 표적으로 하는 등, 맞춤형 치료 전략이 더욱 진전하고 있습니다.

유전자 변이, 건강에 해로운 생활 습관, 환경상의 위험 등의 요인에 의해 AML의 발병률이 증가하고 있기 때문에 혁신적인 치료법의 긴급의 필요성이 강조되고 있습니다. 미국 암학회에 따르면 2025년에 약 22,010명이 급성 골수성 백혈병 진단을 받을 것으로 예상되며, 이는 효과적인 치료 옵션에 대한 수요 증가를 더욱 강조합니다. 2023년 12월, 몬트리올 대학교의 과학자들은 캐나다의 치료 결과를 개선하고 경제 성장을 촉진하기 위해 고위험 급성 골수성 백혈병 환자를 위한 새로운 사이클린 K 분해제를 개발하기 위해 Genome Canada로부터 600만 달러의 보조금을 확보했습니다. 고위험 환자에 대한 혁신적인 치료법의 개발은 연구 개발에의 세계의 다액의 투자와 함께, 시장 성장의 원동력이 될 것으로 예상됩니다.

지역별 시장 점유율 분석(2024년, 2030년)
지역별 시장 대시보드
시장 규모, 예측 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
- 멕시코
유럽
- 국가별(2018-2030년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 국가별(2018-2030년)
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 국가별(2018-2030년)
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별(2018-2030년)
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- DAIICHI SANKYO COMPANY, LIMITED
- Jazz Pharmaceuticals plc
- Novartis AG
- Otsuka Pharmaceuticals Co.,Ltd.
- Pfizer Inc.
- Rigel Pharmaceuticals, Inc.
- Merck KGaA
- Sanofi

KTH 25.04.25

Market Size & Trends:

The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to grow at a CAGR of 10.6% from 2025 to 2030. Rising incidences of acute myeloid leukemia and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.

Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy. Such innovative approaches indicate a growing commitment to developing multifaceted treatment strategies that promise to improve patient outcomes.

Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system's response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.

The growing incidence of AML, driven by factors such as genetic mutations, unhealthy lifestyles, and environmental hazards, underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. In December 2023, scientists at the University of Montreal secured a USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader for high-risk acute myeloid leukemia patients, aiming to enhance treatment outcomes and stimulate economic growth in Canada. The development of innovative therapies for high-risk patients, along with substantial global investments in research and development, is expected to drive market growth. Furthermore, partnerships between pharmaceutical companies and research institutions are enhancing the pace of new AML treatment development.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end use, and region:

Disease Outlook (Revenue, USD Million, 2018 - 2030)
Myeloblastic Leukemia
Myelomonocytic Leukemia
Promyelocytic Leukemia
Monocytic Leukemia
Other Diseases
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Chemotherapy
- Anti-metabolites
- Alkylating Agents
- Anthracycline Drugs
- Others
Targeted Therapy
- FLT3 Inhibitors
- Rydapt
- Vanflyta
- Xospata
- IDH Inhibitors
- Tibsovo
- Rezlidhia
- Idhifa
- Mylotarg
- BCL-2 Inhibitor
- Hedgehog Pathway Inhibitor
Immunotherapy
- Bispecific Antibodies
- Antibody-drug Conjugates
- Immune Checkpoint Inhibitors
- Chimeric Antigen Receptor (CAR) T-cell Therapy
Other Treatments
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Parenteral
Oral
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals and Clinics
Specialty Centers
Homecare Setting
Ambulatory Care Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Disease
- 1.2.2. Treatment
- 1.2.3. Route of Administration
- 1.2.4. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
3.4. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Business Analysis

4.1. Disease Market Share, 2024 & 2030
4.2. Disease Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Myeloblastic Leukemia
- 4.4.1. Myeloblastic Leukemia Market, 2018 - 2030 (USD Million)
4.5. Myelomonocytic Leukemia
- 4.5.1. Myelomonocytic Leukemia Market, 2018 - 2030 (USD Million)
4.6. Promyelocytic Leukemia
- 4.6.1. Promyelocytic Leukemia Market, 2018 - 2030 (USD Million)
4.7. Monocytic Leukemia
- 4.7.1. Monocytic Leukemia Market, 2018 - 2030 (USD Million)
4.8. Other Diseases
- 4.8.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Business Analysis

5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Chemotherapy
- 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
- 5.4.2. Anti-metabolites
- 5.4.3. Anti-metabolites Market, 2018 - 2030 (USD Million)
- 5.4.4. Alkylating Agents
- 5.4.5. Alkylating Agents Market, 2018 - 2030 (USD Million)
- 5.4.6. Anthracycline Drugs
- 5.4.7. Anthracycline Drugs Market, 2018 - 2030 (USD Million)
- 5.4.8. Others
- 5.4.9. Others Market, 2018 - 2030 (USD Million)
5.5. Targeted Therapy
- 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
- 5.5.2. FLT3 Inhibitors
- 5.5.3. FLT3 Inhibitors Market, 2018 - 2030 (USD Million)
  - 5.5.3.1. Rydapt
    - 5.5.3.1.1. Rydapt Market, 2018 - 2030 (USD Million)
  - 5.5.3.2. Vanflyta
    - 5.5.3.2.1. Vanflyta Market, 2018 - 2030 (USD Million)
  - 5.5.3.3. Xospata
    - 5.5.3.3.1. Xospata Market, 2018 - 2030 (USD Million)
- 5.5.4. IDH Inhibitors
- 5.5.5. IDH Inhibitors Market, 2018 - 2030 (USD Million)
  - 5.5.5.1. Tibsovo
    - 5.5.5.1.1. Tibsovo Market, 2018 - 2030 (USD Million)
  - 5.5.5.2. Rezlidhia
    - 5.5.5.2.1. Rezlidhia Market, 2018 - 2030 (USD Million)
  - 5.5.5.3. Idhifa
    - 5.5.5.3.1. Idhifa Market, 2018 - 2030 (USD Million)
- 5.5.6. Mylotarg
  - 5.5.6.1. Mylotarg Market, 2018 - 2030 (USD Million)
- 5.5.7. BCL-2 Inhibitor
  - 5.5.7.1. BCL-2 Inhibitor Market, 2018 - 2030 (USD Million)
- 5.5.8. Hedgehog Pathway Inhibitor
  - 5.5.8.1. Hedgehog Pathway Inhibitor Market, 2018 - 2030 (USD Million)
5.6. Immunotherapy
- 5.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
- 5.6.2. Bispecific Antibodies
  - 5.6.2.1. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.6.3. Antibody-drug Conjugates
  - 5.6.3.1. Antibody-drug Conjugates Market, 2018 - 2030 (USD Million)
- 5.6.4. Immune Checkpoint Inhibitors
  - 5.6.4.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
- 5.6.5. Chimeric Antigen Receptor (CAR) T-cell Therapy
  - 5.6.5.1. Chimeric Antigen Receptor (CAR) T-cell Therapy Market, 2018 - 2030 (USD Million)
5.7. Other Treatments
- 5.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral
- 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
6.5. Oral
- 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Business Analysis

7.1. End Use Market Share, 2024 & 2030
7.2. End Use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Hospitals and Clinics
- 7.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
7.5. Specialty Centers
- 7.5.1. Specialty Centers Market, 2018 - 2030 (USD Million)
7.6. Homecare Setting
- 7.6.1. Homecare Setting Market, 2018 - 2030 (USD Million)
7.7. Ambulatory Care Centers
- 7.7.1. Ambulatory Care Centers Market, 2018 - 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Regulatory Framework
  - 8.4.2.3. Competitive Insights
  - 8.4.2.4. U.S. Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Regulatory Framework
  - 8.4.3.3. Competitive Insights
  - 8.4.3.4. Canada Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Regulatory Framework
  - 8.4.4.3. Competitive Insights
  - 8.4.4.4. Mexico Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Regulatory Framework
  - 8.5.2.3. Competitive Insights
  - 8.5.2.4. UK Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Regulatory Framework
  - 8.5.3.3. Competitive Insights
  - 8.5.3.4. Germany Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Regulatory Framework
  - 8.5.4.3. Competitive Insights
  - 8.5.4.4. France Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Regulatory Framework
  - 8.5.5.3. Competitive Insights
  - 8.5.5.4. Italy Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Regulatory Framework
  - 8.5.6.3. Competitive Insights
  - 8.5.6.4. Spain Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Norway
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Regulatory Framework
  - 8.5.7.3. Competitive Insights
  - 8.5.7.4. Norway Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Denmark
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Regulatory Framework
  - 8.5.8.3. Competitive Insights
  - 8.5.8.4. Denmark Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Sweden
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Regulatory Framework
  - 8.5.9.3. Competitive Insights
  - 8.5.9.4. Sweden Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Regulatory Framework
  - 8.6.2.3. Competitive Insights
  - 8.6.2.4. Japan Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Regulatory Framework
  - 8.6.3.3. Competitive Insights
  - 8.6.3.4. China Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Regulatory Framework
  - 8.6.4.3. Competitive Insights
  - 8.6.4.4. India Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. South Korea
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Regulatory Framework
  - 8.6.5.3. Competitive Insights
  - 8.6.5.4. South Korea Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Australia
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Regulatory Framework
  - 8.6.6.3. Competitive Insights
  - 8.6.6.4. Australia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Regulatory Framework
  - 8.6.7.3. Competitive Insights
  - 8.6.7.4. Thailand Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Regulatory Framework
  - 8.7.2.3. Competitive Insights
  - 8.7.2.4. Brazil Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Regulatory Framework
  - 8.7.3.3. Competitive Insights
  - 8.7.3.4. Argentina Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
- 8.8.1. MEA Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Regulatory Framework
  - 8.8.2.3. Competitive Insights
  - 8.8.2.4. South Africa Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Regulatory Framework
  - 8.8.3.3. Competitive Insights
  - 8.8.3.4. Saudi Arabia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Regulatory Framework
  - 8.8.4.3. Competitive Insights
  - 8.8.4.4. UAE Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Regulatory Framework
  - 8.8.5.3. Competitive Insights
  - 8.8.5.4. Kuwait Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Astellas Pharma Inc.
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Bristol-Myers Squibb Company
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. DAIICHI SANKYO COMPANY, LIMITED
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Jazz Pharmaceuticals plc
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. Novartis AG
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. Otsuka Pharmaceuticals Co.,Ltd.
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Pfizer Inc.
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. Rigel Pharmaceuticals, Inc.
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives
- 9.5.9. Merck KGaA
  - 9.5.9.1. Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product Benchmarking
  - 9.5.9.4. Strategic Initiatives
- 9.5.10. Sanofi
  - 9.5.10.1. Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product Benchmarking
  - 9.5.10.4. Strategic Initiatives

급성 골수성 백혈병 치료 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030

시장 규모와 동향

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 급성 골수성 백혈병 치료 시장 변수, 동향, 범위

제4장 급성 골수성 백혈병 치료 시장 : 질환 비즈니스 분석

제5장 급성 골수성 백혈병 치료 시장 : 치료 비즈니스 분석

제6장 급성 골수성 백혈병 치료 시장 : 투여 경로 비즈니스 분석

제7장 급성 골수성 백혈병 치료 시장 : 최종 용도 비즈니스 분석

제8장 급성 골수성 백혈병 치료 시장 : 지역별, 추정·동향 분석